110 related articles for article (PubMed ID: 3261574)
1. Decreased in vitro lymphocyte stimulation and reduced sensitivity to IL-2 in patients with alopecia areata.
Orecchia G; Capelli E; Martinetti M; Cuccia Belvedere M; Rabbiosi G
Arch Dermatol Res; 1988; 280 Suppl():S47-50. PubMed ID: 3261574
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the topical sensitizer squaric acid dibutyl ester in Alopecia areata and factors influencing the outcome.
Ajith C; Gupta S; Kanwar AJ
J Drugs Dermatol; 2006 Mar; 5(3):262-6. PubMed ID: 16573260
[TBL] [Abstract][Full Text] [Related]
3. Topical immunomodulator therapy with squaric acid dibutylester (SADBE) is effective treatment for severe alopecia areata (AA): results of an open-label, paired-comparison, clinical trial.
Dall'oglio F; Nasca MR; Musumeci ML; La Torre G; Ricciardi G; Potenza C; Micali G
J Dermatolog Treat; 2005 Feb; 16(1):10-4. PubMed ID: 15897160
[TBL] [Abstract][Full Text] [Related]
4. Suppressor cell number and function in alopecia areata.
Hordinsky MK; Hallgren H; Nelson D; Filipovich AH
Arch Dermatol; 1984 Feb; 120(2):188-94. PubMed ID: 6230058
[TBL] [Abstract][Full Text] [Related]
5. [Significance of HLA-DR+ T cells and natural killer (NK) cells in the peripheral blood lymphocytes of alopecia areata (AA)].
Imai R
Nihon Hifuka Gakkai Zasshi; 1990 Oct; 100(11):1143-52. PubMed ID: 2273577
[TBL] [Abstract][Full Text] [Related]
6. Squaric acid sensitization is not required for response in the treatment of alopecia areata.
Vedak P; Kroshinsky D
J Am Acad Dermatol; 2015 Sep; 73(3):471-6. PubMed ID: 26282797
[TBL] [Abstract][Full Text] [Related]
7. The protective role of the HLA-DR locus in patients with various clinical types of alopecia areata.
Broniarczyk-Dyła G; Prusińska-Bratoś M; Dubla-Berner M; Arkuszewska C; Borowiec M; Kowalski ML; Woszczek G
Arch Immunol Ther Exp (Warsz); 2002; 50(5):333-6. PubMed ID: 12455867
[TBL] [Abstract][Full Text] [Related]
8. Influence of ascorbic acid on the response to mitogens and interleukin production of porcine lymphocytes.
Schwager J; Schulze J
Int J Vitam Nutr Res; 1997; 67(1):10-6. PubMed ID: 9119607
[TBL] [Abstract][Full Text] [Related]
9. Modified immunotherapy for alopecia areata.
Yoshimasu T; Furukawa F
Autoimmun Rev; 2016 Jul; 15(7):664-7. PubMed ID: 26932732
[TBL] [Abstract][Full Text] [Related]
10. In vivo levels of IL-4, IL-10, TGF-beta1 and IFN-gamma mRNA of the peripheral blood mononuclear cells in patients with alopecia areata in comparison to those in patients with atopic dermatitis.
Katagiri K; Arakawa S; Hatano Y
Arch Dermatol Res; 2007 Jan; 298(8):397-401. PubMed ID: 17021766
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 receptor alpha-chain expression in patients with alopecia areata.
Brajac I; Gruber F; Petrovecki M; Malnar-Dragojević D
Acta Dermatovenerol Croat; 2004; 12(3):154-6. PubMed ID: 15369638
[TBL] [Abstract][Full Text] [Related]
12. Topical therapy of alopecia areata with squaric acid dibutylester.
Case PC; Mitchell AJ; Swanson NA; Vanderveen EE; Ellis CN; Headington JT
J Am Acad Dermatol; 1984 Mar; 10(3):447-50. PubMed ID: 6725657
[TBL] [Abstract][Full Text] [Related]
13. Strong expression of CD40, CD54 and HLA-DR antigen and lack of evidence for direct cellular cytotoxicity are unique immunohistopathological features in alopecia areata.
Sato-Kawamura M; Aiba S; Tagami H
Arch Dermatol Res; 2003 Mar; 294(12):536-43. PubMed ID: 12624779
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic and functional analysis of peripheral blood mononuclear cells in generalised aggressive and chronic periodontitis patients.
Emingil G; Karaarslan F; Keskinoğlu A; Coker I; Atilla G
J Int Acad Periodontol; 2001 Oct; 3(4):87-94. PubMed ID: 12666947
[TBL] [Abstract][Full Text] [Related]
15. Discoid lupus erythematosus exacerbated by contact dermatitis caused by use of squaric acid dibutylester for topical immunotherapy in a patient with alopecia areata.
Shimaoka Y; Hatamochi A; Hamasaki Y; Suzuki H; Ikeda H; Yamazaki S
J Dermatol; 2008 Mar; 35(3):151-3. PubMed ID: 18346258
[TBL] [Abstract][Full Text] [Related]
16. Mitogenic response and interleukin 2 production in Crohn's disease.
Miura M; Hiwatashi N
J Clin Lab Immunol; 1987 Nov; 24(3):113-6. PubMed ID: 3501474
[TBL] [Abstract][Full Text] [Related]
17. Dissociation in the production of B cell-stimulating factors (BCGF and BCDF) and interleukin 2 by T cells from a common variable immunodeficient patient.
Saiki O; Shimizu M; Saeki Y; Kishimoto S; Kishimoto T
J Immunol; 1984 Oct; 133(4):1920-4. PubMed ID: 6088629
[TBL] [Abstract][Full Text] [Related]
18. [Alopecia areata and treatment with the diethylester of squaric acid. Behavior of lymphocyte subpopulations].
Pigatto PD; Gini R; Altomare GF
G Ital Dermatol Venereol; 1985; 120(3):227-30. PubMed ID: 4030021
[No Abstract] [Full Text] [Related]
19. Squaric acid dibutylester: indications for use and efficacy in alopecia areata.
Pardasani AG; Turner E; McMichael AJ
Arch Dermatol; 2001 Jul; 137(7):970-2. PubMed ID: 11453831
[No Abstract] [Full Text] [Related]
20. [Increase in the activated (HLA-DR+) T-cells in the peripheral blood lymphocyte of patients with alopecia areata].
Imai R; Miura J; Numata K; Aikawa Y; Takamori K; Ogawa H
Nihon Hifuka Gakkai Zasshi; 1988 Mar; 98(3):355-60. PubMed ID: 3261812
[No Abstract] [Full Text] [Related]
[Next] [New Search]
